Want to see UPB full AI Analyst Report?
Top Page
Upstream Bio, Inc.
(NASDAQ:UPB)
Select Model
Select Model
Rating:52Neutral
Price Target:
$6.50
▲(1.40% Upside)
Action:Reiterated
Date:07/09/26
The score is primarily held back by weak financial performance: heavy losses and worsening cash burn outweigh modest revenue growth, despite a strong, low-debt balance sheet. Technicals are mixed (short-term support but longer-term downtrend), and valuation is constrained by negative earnings and no dividend support.
Positive Factors
Low leverage / strong balance sheet
Very low debt and a large equity base give the company structural financial flexibility to fund R&D, absorb trial delays, and pursue partnerships without immediate refinancing pressure. This reduces bankruptcy and interest-rate risks across the 2–6 month horizon.
Negative Factors
Accelerating cash burn
Worsening negative operating and free cash flow creates structural runway risk: the company will likely need additional financing or partnerships to sustain programs. That raises dilution and forces prioritization of programs over the next several months.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt and a large equity base give the company structural financial flexibility to fund R&D, absorb trial delays, and pursue partnerships without immediate refinancing pressure. This reduces bankruptcy and interest-rate risks across the 2–6 month horizon.
Read all positive factors
Upstream Bio, Inc. (UPB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$343.39M
Dividend YieldN/A
Average Volume (3M)586.81K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees75
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.91
Shares Outstanding54,419,987
10 Day Avg. Volume463,820
30 Day Avg. Volume586,814
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.33Price Target Upside560.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.8
Revenue Forecast (FY)$2.03M
Upstream Bio, Inc. Business Overview & Revenue Model
Company Description
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a ...
How the Company Makes Money
null...
Upstream Bio, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
74
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.32M | 2.85M | 2.37M | 2.38M | 1.21M |
| Gross Profit | 3.27M | 2.85M | 2.37M | 2.38M | 1.21M |
| EBITDA | -156.57M | -143.25M | -62.72M | -20.48M | -23.86M |
| Net Income | -156.76M | -143.44M | -62.81M | -20.54M | -23.87M |
Balance Sheet | |||||
| Total Assets | 318.05M | 353.77M | 481.72M | 117.20M | 18.48M |
| Cash, Cash Equivalents and Short-Term Investments | 294.58M | 341.51M | 470.45M | 109.81M | 17.05M |
| Total Debt | 1.11M | 1.27M | 1.83M | 45.00K | 94.00K |
| Total Liabilities | 14.06M | 14.00M | 11.87M | 240.32M | 124.63M |
| Stockholders Equity | 304.00M | 339.77M | 469.85M | -123.13M | -106.16M |
Cash Flow | |||||
| Free Cash Flow | -140.01M | -133.28M | -59.68M | -38.07M | -19.10M |
| Operating Cash Flow | -139.96M | -133.28M | -59.17M | -37.93M | -19.02M |
| Investing Cash Flow | 162.30M | -93.48M | -59.48M | -82.84M | -82.00K |
| Financing Cash Flow | 3.07M | 2.44M | 418.91M | 129.55M | 9.96M |
Upstream Bio, Inc. Technical Analysis
Negative
6.41
Price Trends
7.02
Negative
8.16
Negative
15.90
Negative
Market Momentum
-0.23
Positive
39.12
Neutral
34.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPB, the sentiment is Negative. The current price of 6.41 is below the 20-day moving average (MA) of 6.95, below the 50-day MA of 7.02, and below the 200-day MA of 15.90, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 39.12 is Neutral, neither overbought nor oversold. The STOCH value of 34.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UPB.
Upstream Bio, Inc. Risk Analysis
Upstream Bio, Inc. disclosed 80 risk factors in its most recent earnings report. Upstream Bio, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Upstream Bio, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $365.91M | 5.00 | 41.40% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | $343.39M | -2.17 | -43.82% | ― | ― | ― | |
50 Neutral | $163.72M | -2.04 | -36.55% | ― | -67.73% | -11.57% | |
49 Neutral | $395.93M | -2.10 | -677.38% | ― | 7.97% | 59.82% | |
49 Neutral | $144.80M | -1.03 | -100.13% | ― | 12.96% | 12.51% | |
47 Neutral | $339.59M | -1.66 | -70.79% | ― | ― | 28.56% |
* General Sector Average
UPB
Upstream Bio, Inc.
6.42
-9.19
-58.87%
ARCT
Arcturus Therapeutics
6.00
-6.20
-50.82%
RCKT
Rocket Pharmaceuticals
3.41
0.34
11.07%
ABEO
Abeona Therapeutics
6.39
-0.03
-0.47%
EDIT
Editas Medicine
2.65
0.09
3.52%
CRBU
Caribou Biosciences
1.50
-0.60
-28.57%
Upstream Bio, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor
Neutral
Jun 10, 2026
Upstream Bio, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, with 48,100,767 of 54,419,986 eligible shares represented, establishing a quorum for business. Shareholders voted on electing two Class II directors, H. Edward Flemin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.